[{"orgOrder":0,"company":"OncoBay Clinical","sponsor":"Hillstream BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"HSB-1216","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OncoBay Clinical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OncoBay Clinical \/ Hillstream BioPharma","highestDevelopmentStatusID":"5","companyTruncated":"OncoBay Clinical \/ Hillstream BioPharma"}]

Find Clinical Drug Pipeline Developments & Deals by OncoBay Clinical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the agreement, OncoBay will provide comprehensive clinical and regulatory support for the clinical development program for Hillstream's lead drug HSB-1216, which targets ferroptosis, an emerging new anti-cancer mechanism, resulting in IMCD of drug ...

                          Brand Name : HSB-1216

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 13, 2023

                          Lead Product(s) : HSB-1216

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Hillstream BioPharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank